Deoxycoformycin in the Treatment of Leukemias and Lymphomas a
暂无分享,去创建一个
J. Smyth | A. Hoffbrand | H. G. Prentice | S. Proctor | STEPHEN PROCTOR | A. VICTOR HOFFBRAND | H. Prentice
[1] A. Piga,et al. THERAPEUTIC SELECTIVITY OF AND PREDICTION OF RESPONSE TO 2'-DEOXYCOFORMYCIN IN ACUTE LEUKAEMIA , 1981, The Lancet.
[2] A. Piga,et al. Studies on the Biochemical Sequelae of Therapy in Thy‐Acute Lymphoblastic Leukaemia with the Adenosine Deaminase Inhibitor 2’Deoxycoformycin , 1981, British journal of haematology.
[3] S. Sallan,et al. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. , 1981, Cancer research.
[4] G. Janossy,et al. REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIA , 1980, The Lancet.
[5] J. Smyth,et al. Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. , 1978, Journal of Clinical Investigation.
[6] T. Spector,et al. Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. , 1977, Biochemical pharmacology.
[7] J. Smyth,et al. Adenosine deaminase activity in leukaemia. , 1975, British Journal of Cancer.
[8] J. Dissing,et al. Adenosine-deaminase deficiency and combined immunodeficiency syndrome. , 1972, Lancet.
[9] E. Giblett,et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.